← Oncology Approval Tracker

FDA DECISION ·

Albumin-bound paclitaxel (first generic)

paclitaxel protein-bound particles for injectable suspension (albumin-bound) · Jiangsu Hengrui Pharmaceuticals

First generic approvalFirst genericBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The first generic to the referenced albumin-bound paclitaxel suspension, listed for metastatic breast cancer after combination chemotherapy failure or relapse within six months of adjuvant chemotherapy.

LAMPGEN ANALYSIS

Why it matters

This approval concerns the albumin-bound product and the generic’s labeled breast cancer use.

What research teams should watch

Keep conventional and albumin-bound paclitaxel separate in orders and check the generic label before using a reference-product indication.

PRIMARY RECORDS

Sources